ArticleBMC complementary medicine and therapies2026
Evaluation of subchronic oral dose toxicity of Antrodia camphorata mycelium powder in rodents as a novel food source.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antrodia camphorata (A. camphorata), also known as "Niuchangchih" in Taiwan, is a medicinal fungus traditionally used for its hepatoprotective, anti-inflammatory, and anticancer properties. However, the safety and potential toxic effects of its mycelium form have not yet been fully established. This study aimed to evaluate the subchronic oral toxicity and determine the no observed adverse effect level (NOAEL) of A. camphorata mycelium powder in Sprague Dawley (SD) rats under Good Laboratory Practice (GLP)-compliant conditions.SD rats (10/sex/group) were administered A. camphorata mycelium powder orally at doses of 0, 500, 1000, and 2000 mg/kg/day as a 10 ml/kg/day suspension in water for 13 weeks. A 4-week recovery study was conducted at 0 and 2000 mg/kg/day with 5 rats/sex/group.Dose-dependent increases in liver and adrenal weights were noted, accompanied by hepatocellular and adrenal cortical hypertrophy, which were fully reversed in males and showed a tendency toward recovery in females after the recovery period. Repeated oral administration of A. camphorata mycelium powder for 13 weeks produced no adverse systemic toxicity in rats. The NOAEL was determined to be 2000 mg/kg/day in both sexes, supporting its safety for further development as a functional food or medicinal product. These findings provide important safety data supporting its further application in health supplements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.